HU0600226A3 - Conformationally constrained analogs useful as antidiabetic and antiobesity agents and their medical use - Google Patents

Conformationally constrained analogs useful as antidiabetic and antiobesity agents and their medical use

Info

Publication number
HU0600226A3
HU0600226A3 HU0600226A HU0600226A HU0600226A3 HU 0600226 A3 HU0600226 A3 HU 0600226A3 HU 0600226 A HU0600226 A HU 0600226A HU 0600226 A HU0600226 A HU 0600226A HU 0600226 A3 HU0600226 A3 HU 0600226A3
Authority
HU
Hungary
Prior art keywords
antidiabetic
medical use
conformationally constrained
antiobesity agents
analogs useful
Prior art date
Application number
HU0600226A
Other versions
HU0600226A2 (en
Original Assignee
Squibb Bristol Myers Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US29450501P priority Critical
Application filed by Squibb Bristol Myers Co filed Critical Squibb Bristol Myers Co
Priority to PCT/US2002/016628 priority patent/WO2002096357A2/en
Publication of HU0600226A2 publication Critical patent/HU0600226A2/en
Publication of HU0600226A3 publication Critical patent/HU0600226A3/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
HU0600226A 2001-05-30 2002-05-23 Conformationally constrained analogs useful as antidiabetic and antiobesity agents and their medical use HU0600226A3 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US29450501P true 2001-05-30 2001-05-30
PCT/US2002/016628 WO2002096357A2 (en) 2001-05-30 2002-05-23 Conformationally constrained analogs useful as antidiabetic and antiobesity agents and method

Publications (2)

Publication Number Publication Date
HU0600226A2 HU0600226A2 (en) 2006-11-28
HU0600226A3 true HU0600226A3 (en) 2012-09-28

Family

ID=23133727

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0600226A HU0600226A3 (en) 2001-05-30 2002-05-23 Conformationally constrained analogs useful as antidiabetic and antiobesity agents and their medical use

Country Status (9)

Country Link
US (2) US7105556B2 (en)
EP (1) EP1401433B1 (en)
JP (1) JP4365587B2 (en)
AT (1) AT487493T (en)
CA (1) CA2449006A1 (en)
DE (1) DE60238255D1 (en)
ES (1) ES2354149T3 (en)
HU (1) HU0600226A3 (en)
WO (1) WO2002096357A2 (en)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1214304B1 (en) * 1999-08-31 2005-08-24 Incyte San Diego Incorporated Benzylidene-thiazolidinediones and analogues and their use in the treatment of diabetes
TW200300681A (en) * 2001-11-12 2003-06-16 Ono Pharmaceutical Co Carboxylic acid derivative compound and medicament containing same as active ingredient
AU2003259131A1 (en) * 2002-07-09 2004-01-23 Bristol-Myers Squibb Company Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method
CN1894234A (en) * 2003-03-25 2007-01-10 武田药品工业株式会社 Dipeptidyl peptidase inhibitors
AT442365T (en) * 2003-05-20 2009-09-15 Novartis Pharma Gmbh N-acyl nitrogen heterocycles as ligands of peroxisom proliferator-activated receptors
US7723344B2 (en) * 2003-08-13 2010-05-25 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
US7169926B1 (en) 2003-08-13 2007-01-30 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7678909B1 (en) 2003-08-13 2010-03-16 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US20050054731A1 (en) * 2003-09-08 2005-03-10 Franco Folli Multi-system therapy for diabetes, the metabolic syndrome and obesity
WO2005026148A1 (en) * 2003-09-08 2005-03-24 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
EP1697342A2 (en) * 2003-09-08 2006-09-06 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7732446B1 (en) 2004-03-11 2010-06-08 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
CA2559302C (en) * 2004-03-15 2012-06-19 Takeda Pharmaceutical Company Limited 6-amino-1h-pyrimidine-2,4-dione derivatives as dipeptidyl peptidase inhibitors
JP2008501714A (en) * 2004-06-04 2008-01-24 武田薬品工業株式会社 Dipeptidyl peptidase inhibitor
US8226977B2 (en) 2004-06-04 2012-07-24 Teva Pharmaceutical Industries Ltd. Pharmaceutical composition containing irbesartan
WO2006019965A2 (en) 2004-07-16 2006-02-23 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
WO2006011397A1 (en) * 2004-07-27 2006-02-02 Kowa Company., Ltd. Drug for prevention or treatment of diabetes
CA2590182A1 (en) * 2004-12-14 2006-06-22 Shionogi & Co., Ltd. Indolomorphinan derivatives having carboxy at the 6'-position
EP2805953B1 (en) 2004-12-21 2016-03-09 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US20070015839A1 (en) * 2005-07-14 2007-01-18 Franco Folli Daily Dosage Regimen for Treating Diabetes, Obesity, Metabolic Syndrome and Polycystic Ovary Syndrome
WO2007014023A1 (en) * 2005-07-21 2007-02-01 Valeant Research & Development Thiazolidinones, oxazolidinones, and pyrrolidinones for hbv
JP5791228B2 (en) * 2006-09-13 2015-10-07 武田薬品工業株式会社 Use of 2-6- (3-amino-piperidin-1-yl) -3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethyl-4-fluoro-benzonitrile
US20070060530A1 (en) * 2005-09-14 2007-03-15 Christopher Ronald J Administration of dipeptidyl peptidase inhibitors
WO2007033266A2 (en) * 2005-09-14 2007-03-22 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors for treating diabetis
TW200745080A (en) * 2005-09-16 2007-12-16 Takeda Pharmaceuticals Co Polymorphs of tartrate salt of 2-[2-(3-(R)-amino-piperidin-1-yl)-5-fluoro-6-oxo-6H-pyrimidin-1-ylmethyl]-benzonitrile and methods of use therefor
US8324383B2 (en) 2006-09-13 2012-12-04 Takeda Pharmaceutical Company Limited Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
TW200745079A (en) * 2005-09-16 2007-12-16 Takeda Pharmaceuticals Co Polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile and methods of use therefor
EP1924567B1 (en) 2005-09-16 2012-08-22 Takeda Pharmaceutical Company Limited Process for the preparation of pyrimidinedione derivatives
WO2007112368A1 (en) * 2006-03-28 2007-10-04 Takeda Pharmaceutical Company Limited Preparation of (r)-3-aminopiperidine dihydrochloride
WO2007112347A1 (en) 2006-03-28 2007-10-04 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
TW200838536A (en) * 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
US8093236B2 (en) 2007-03-13 2012-01-10 Takeda Pharmaceuticals Company Limited Weekly administration of dipeptidyl peptidase inhibitors
TW200906823A (en) * 2007-07-16 2009-02-16 Lilly Co Eli Compounds and methods for modulating FXR
EP2679224A1 (en) 2007-08-01 2014-01-01 University of Pittsburgh of the Commonwealth System of Higher Education Nitro oleic acid modulation of type II diabetes
KR101552187B1 (en) 2007-09-10 2015-09-10 얀센 파마슈티카 엔.브이. Process for the preparation of compounds useful as inhibitors of sglt
JP2011519373A (en) 2008-05-01 2011-07-07 コンプレクザ インコーポレイテッド Vinyl-substituted fatty acids
CN102099024B (en) 2008-06-19 2015-11-25 犹他大学研究基金会 Nitrated lipid use in the treatment of side effects of toxic medical therapy
US20140024713A1 (en) 2008-06-19 2014-01-23 University Of Utah Research Foundation Use of nitrated lipids for treatment of side effects of toxic medical therapies
US9056850B2 (en) 2008-10-17 2015-06-16 Janssen Pharmaceutica N.V. Process for the preparation of compounds useful as inhibitors of SGLT
US9066902B2 (en) 2009-07-31 2015-06-30 University of Pittsburgh—of the Commonwealth System of Higher Education Fatty acids as anti-inflammatory agents
WO2011041639A2 (en) 2009-10-02 2011-04-07 Miller Raymond A Heteroatom containing substituted fatty acids
US9174971B2 (en) 2009-10-14 2015-11-03 Janssen Pharmaceutica Nv Process for the preparation of compounds useful as inhibitors of SGLT2
SI2513053T1 (en) * 2009-12-18 2018-02-28 Ogeda Sa Pyrrolidine carboxylic acid derivatives as agonists of G-protein coupled receptor 43 (GPR43), pharmaceutical composition and methods for use in treating metabolic disorders
JP2013534930A (en) * 2010-06-28 2013-09-09 コンプレクサ,インコーポレイテッドComplexa,Inc. Multi-component formulation for the treatment of diabetes
US9035044B2 (en) 2011-05-09 2015-05-19 Janssen Pharmaceutica Nv L-proline and citric acid co-crystals of (2S, 3R, 4R, 5S,6R)-2-(3-((5-(4-fluorophenyl)thiopen-2-yl)methyl)4-methylphenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol
EP2744491A4 (en) 2011-08-19 2015-01-14 Univ Utah Res Found Combination therapy with nitrated lipids and inhibitors of the renin-angiotensin-aldosterone system
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS584711B2 (en) 1978-08-02 1983-01-27 Santen Pharma Co Ltd
FR2678938B1 (en) 1991-07-10 1993-10-08 Rhone Poulenc Rorer Sa Pyrrolidine derivatives, their preparation and medicines containing them.
TW200528436A (en) 1999-09-22 2005-09-01 Squibb Bristol Myers Co Substituted acid derivatives useful as antiodiabetic and antiobesity agents and method
MXPA02004647A (en) 1999-11-10 2002-10-31 Takeda Chemical Industries Ltd 5 membered n heterocyclic compounds with hypoglycemic and hypolipidemic activity.

Also Published As

Publication number Publication date
WO2002096357A2 (en) 2002-12-05
WO2002096357A3 (en) 2003-09-25
CA2449006A1 (en) 2002-12-05
EP1401433B1 (en) 2010-11-10
EP1401433A4 (en) 2005-10-12
US7452907B2 (en) 2008-11-18
JP2005506954A (en) 2005-03-10
ES2354149T3 (en) 2011-03-10
HU0600226A2 (en) 2006-11-28
EP1401433A2 (en) 2004-03-31
DE60238255D1 (en) 2010-12-23
US7105556B2 (en) 2006-09-12
US20030092697A1 (en) 2003-05-15
AT487493T (en) 2010-11-15
US20060189598A1 (en) 2006-08-24
JP4365587B2 (en) 2009-11-18

Similar Documents

Publication Publication Date Title
DE50205264D1 (en) Aminoalkylalkoxysiloxane-containing mixtures, their preparation and their use
DE60215919D1 (en) 4-fluoro-n-indan-2-yl benzamide and its use as a medicament
DE60140126D1 (en) 2-aminopyridine compounds and their use as medicaments
GB2394726B (en) Fabric care composition comprising fabric or skin beneficiating ingredient
DK1401806T3 (en) Benzoylsulfonamides and sulfonylbenzamidines for use as antitumor agents
GB2397770B (en) Disposable absorbent article
DE50210271D1 (en) Amphotere liposomes and use thereof
DK1417175T3 (en) Substituted dihydro-3-halo-1h-pyrazol-5-carboxylates and preparation and use thereof
DE60125344D1 (en) Formulations for use in inhalation devices
DE60208351D1 (en) Glucopyranosyloxybenzylbenzole derivatives and their medical use
DE60230591D1 (en) Glycopyranosyloxypyrazole derivatives and their medical use
DE60237580D1 (en) Glycopyranosyloxypyrazole derivatives and their medical use
DK1372608T3 (en) Medical aerosol formulations
DE60224964D1 (en) Respiratory equipment for use in examining the respiratory mechanics of a respiratory system
DE60123420D1 (en) Cyclohexyl derivatives and their use as therapeutic agents
PL1663168T3 (en) Nicotine formulations and use thereof
AU2002351311A8 (en) Medical device
PT1913939T (en) Formulations for use in inhaler devices
GB0100981D0 (en) Surgical tables
GB0011053D0 (en) Medical device and use thereof
ZA200600125B (en) Pyridazine derivatives and their use as therapeutic agents
IL173395D0 (en) Pyridazine derivatives and their use as therapeutic agents
GB0103973D0 (en) Improvements relating to skin prickers
IL173032D0 (en) Pyridazine derivatives and their use as therapeutic agents
HK1079109A1 (en) Vaginal care composition

Legal Events

Date Code Title Description
FC4A Lapse of provisional application due to refusal